Clinical Trial Update: A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) [Phase 2, Phase 3]

View source ↗

Summary

This update reports completion of Phase 2/Phase 3 trials of caplacizumab in Japanese patients with acquired thrombotic thrombocytopenic purpura.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

Sponsor: Sanofi | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 2, Phase 3 | Status: COMPLETED